Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD |
ฝัง
- เผยแพร่เมื่อ 1 ม.ค. 2025
- Dr. Anne Kramer from Stanford University discusses the use of CD22-targeting CAR T-cell therapy for patients who have relapsed following CD19-targeting CAR-T therapy.
Link to ASH playlist on HTU: healthtree.org...
ASH Abstract: CD22-Directed CAR T-Cell Therapy for Large B-Cell Lymphomas Progressing after CD19-Directed CAR T-Cell Therapy: Continued Durable Remissions at 3-Year Follow-up
#ASH24 #DLBCL #lymsm
Follow HealthTree: linktr.ee/Heal...